AOD-9604 (5 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency is once daily by subcutaneous injection, morning fasted. The timing is mechanistic rather than arbitrary: AOD-9604 mobilizes fatty acids into circulation, and without oxidative demand those fatty acids re-esterify back into storage. The sequence is to inject, wait 30 to 60 minutes for beta-3 receptor activation, then perform Zone-2 cardio or fasted training. Injecting at night before bed wastes the dose, because there is no demand and therefore no burn. Abdominal fat is the preferred injection site for its high density of subcutaneous adipose tissue, rotating quadrants around the navel and staying at least 2 inches away from it; the outer thigh and the back of the upper arm are alternatives. At 5 mg/mL a 300 mcg dose is 6 units and a 500 mcg dose is 10 units (0.10 mL), so a 30 unit barrel gives the best accuracy at these volumes.

Results Timeline

Sequence described in the research record. Individual response varies.

• Daily: inject morning fasted, then wait 30 to 60 minutes for beta-3 receptor activation before Zone-2 cardio or fasted training.
• Weeks 1 to 4: standard 300 mcg daily. Effect size is small and gradual; this is a marginal optimizer, not a primary driver.
• Week 4: evaluation checkpoint. No measurable change by week 4 means the bottleneck is upstream in diet, training, sleep, or the primary fat loss compounds, and continuing will not help.
• Weeks 4 to 16: continue at 300 mcg daily where the response is measurable, with 500 mcg reserved for heavier individuals.
• End of cycle: 4 weeks off after 12 to 16 weeks on before repeating.

Reconstitution Steps

1. Draw 1.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light, and use within 4 to 6 weeks. At 5 mg/mL, 1 unit = 0.01 mL » 50 mcg on a U-100 insulin syringe, so 250 mcg is 5 units, 300 mcg is 6 units, and 500 mcg is 10 units (0.10 mL).

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at minus 20 °C in dry, dark conditions; stable for at least 1 year.
• Reconstituted: refrigerate at 2 to 8 °C, use within 4 to 6 weeks, and protect from light and temperature fluctuations.

• Allow vials to reach room temperature before opening to reduce condensation uptake.
• Avoid freeze-thaw cycles; keep vials in the original carton or another opaque container.

Supplies Needed

Planning math is based on a 12 to 16 week cycle at 300 mcg daily, morning fasted, which works out to 2.1 mg per week.

Peptide Vials (AOD-9604, 5 mg vial):

• A 12 week cycle at 300 mcg daily totals roughly 25 mg, about 5 vials of 5 mg each; a 16 week cycle totals roughly 34 mg, about 7 vials. At 300 mcg daily each 5 mg vial covers about 16 to 17 days, which sits inside the 4 to 6 week window for reconstituted material.

Insulin Syringes (U-100):

• Per week: 7 U-100 insulin syringes, one per day, with 30 unit barrels preferred for accuracy at a 6 unit draw.
• Full cycle: 84 syringes over 12 weeks, or 112 over 16 weeks.

Bacteriostatic Water (10 mL bottles):

• At 1.0 mL of bacteriostatic water per 5 mg vial, one 10 mL bottle covers 10 vials, so a single bottle covers a 12 week cycle of about 5 vials or a 16 week cycle of about 7 vials.

Alcohol Swabs:

• Per injection: 2 alcohol swabs, one for the vial stopper and one for the skin, which is 14 per week.
• Full cycle: 168 swabs over 12 weeks or 224 over 16 weeks, which is 2 to 3 boxes of 100.

Important Notes

Practical considerations for consistency and safety.

• Layer 5 only. The effect size is small. Where diet, training, sleep, and the primary fat loss compounds such as GLP-1 agonists and tesamorelin are not already dialed in, AOD-9604 will not rescue the protocol.
• Pair with activity, always. Mobilization without oxidation is the failure mode, because mobilized fatty acids re-esterify back into adipocytes when there is no oxidative demand. Morning fasted dosing followed by Zone-2 cardio or training within 30 to 60 minutes is the protocol, not an optional refinement.
• Evaluation checkpoint at week 4. No measurable change by week 4 means the bottleneck is elsewhere, and continuing will not help. Inject into abdominal fat preferentially, rotating quadrants around the navel and staying at least 2 inches away, with the outer thigh and the back of the upper arm as alternatives.
• Pair with tesamorelin during aggressive cuts. AOD-9604 provides zero anabolic protection, so running it through a hard deficit without tesamorelin risks disproportionate muscle loss. AOD-9604 goes in the morning, fasted and pre-activity; tesamorelin goes in the evening for pulsatile growth hormone during sleep.
• Stacking partners documented in the literature include the Morning Partition Stack, in which AOD-9604 mobilizes, L-carnitine transports, MOTS-c programs mitochondria to prefer fat as fuel, and activity creates the demand; tesamorelin for anabolic protection at layer 4; and GLP-1 agonists as primary fat loss at layer 3, a completely different mechanism with no interaction concerns. Side effects are occasional injection site reactions, occasional headache, and rare nausea or GI upset, indistinguishable from placebo across six RCTs. No IGF-1 or glucose bloodwork is required to run it.
• Regulatory Note: AOD-9604 is not approved as a therapeutic anywhere. It failed Phase IIb trials for obesity in 2007 and development was discontinued; it holds FDA GRAS status granted in 2019 for food-ingredient use, which reinforces the safety signal but does not constitute therapeutic approval. It is WADA prohibited under category S2, Peptide Hormones, Growth Factors, and Related Substances, and its metabolites are detectable, so it falls outside any protocol for individuals subject to drug testing in any capacity.

How This Works

AOD-9604 binds to adipocytes and upregulates beta-3 adrenergic receptors, the receptor subtype primarily responsible for catecholamine driven lipolysis in fat tissue. Increased beta-3 activity drives hormone-sensitive lipase, which hydrolyzes stored triglycerides into free fatty acids released into circulation. The mechanistic proof comes from Heffernan 2001 in Endocrinology: in beta-3 adrenergic receptor knockout mice AOD-9604 produced no lipolytic effect at all, while normal mice showed clear fat reduction. No beta-3 receptors, no response. Human beta-3 expression varies between individuals, which likely explains why some respond clearly and others see nothing. The tyrosine residue added at position 177 of the hGH 177 to 191 fragment stabilizes the molecule and blocks residual growth hormone like effects such as IGF-1 elevation, glucose disruption, and growth signaling, leaving a pure lipolytic signal isolated from the rest of the growth hormone cascade. The critical conceptual frame is that mobilization is not oxidation: AOD-9604 opens the door and activity burns what comes out. Without oxidative demand from training or cardio, mobilized fatty acids simply re-esterify and return to adipocytes, which is why morning fasted dosing paired with activity is non-negotiable for the compound to do anything measurable.

Benefits & Side Effects

Observations from the published record.

• Lipolytic activation: beta-3 receptor upregulation and hormone-sensitive lipase activation drive fatty acid release from adipocytes.
• Phase IIb clinical effect: approximately 2% body weight reduction versus placebo over 24 weeks in 534 obese adults in the OPTIONS trial. Clinically insufficient for obesity, mechanistically real for marginal recomposition.
• Exceptional safety profile: indistinguishable from placebo across six RCTs in Stier 2013, with no IGF-1 elevation, no OGTT abnormalities, no anti-AOD antibodies, no edema, no carpal tunnel, and no pituitary suppression. No growth hormone axis monitoring is required, unlike tesamorelin or hGH.
• FDA GRAS status granted in 2019 for food-ingredient use, unusual for a bioactive peptide, reinforcing the safety signal even though it does not constitute therapeutic approval.
• Responder variation: beta-3 receptor expression varies between individuals, so some respond clearly while others see nothing, and the mechanism is intact regardless of dose. Side effects are limited to occasional injection site reactions, occasional headache, and rare nausea or GI upset.
• WADA prohibited under category S2 despite minimal performance enhancement, because its origin as a growth hormone fragment places it on the prohibited list.

Lifestyle Factors

Complementary strategies for best outcomes.

• Diet is layer 1: a caloric deficit is non-negotiable, since AOD-9604 has nothing to mobilize against when there is no demand for stored energy. Protein at 1.6 to 2.2 g per kg of body weight protects lean mass through the deficit.
• Training is layer 2: resistance training 3 to 4 times per week preserves lean mass during fat loss, and Zone-2 cardio in a fasted state maximizes fatty acid oxidation. Morning activity immediately after injection is what turns the lipolytic signal into measurable fat loss.
• Sleep of 7 to 9 hours supports recovery, hormonal regulation, and adherence across a 12 to 16 week cycle.
• Realistic expectations: this compound suits someone seeking the final 2 to 3% of body fat reduction, not the first 20%. Significant fat loss requires GLP-1 agonists at layer 3.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Heffernan M et al. Beta-3 receptor knockout study; AOD-9604 mechanism (Endocrinology, 2001).
2. Stier H, Vos E, Kenley D. Safety and tolerability of AOD9604 in humans across six RCTs (J Endocrinol Metab, 2013).
3. Ng FM et al. Metabolic effects of AOD9604 on obese Zucker rats (J Mol Endocrinol, 2000).
4. Cox HD et al. Detection and metabolism of AOD9604; WADA testing context (Drug Test Anal, 2015).
5. Wilding J. AOD-9604 Metabolic; Phase IIb clinical review (Curr Opin Investig Drugs, 2004).